From Laboratory to Clinic: Overcoming Immunotherapy Failure
Wednesday, February 19, 2025
12:00 pm - 1:00 pm
About the Event
Tumor cells evade immune surveillance and modulate the tumor microenvironment, driving resistance to chemo- and immunotherapies. Through a phase II/IIb clinical trial on oncolytic viral gene therapy, mechanisms and biomarkers of resistance were identified, informing preclinical studies and future clinical trials. This talk will explore a tumor intrinsic factor linked to chemotherapy resistance and extracellular factors contributing to immune therapy failure. The research aims to counteract tumor-mediated therapeutic failure and develop impactful new clinical trials.
About the Speaker
Shu-Hsia Chen, Ph.D., is a professor and director of the Cancer Immunotherapy Research Center at Houston Methodist Research Institute. She has made significant contributions to gene therapy and cancer immunotherapy, including inventing adenoviral gene delivery of suicide and immune modulatory genes, evaluating how myeloid derived suppressor cells (MDSC) mediate immune responses, and identifying novel immune checkpoint receptors on MDSC populations. Her current research focuses on overcoming immune suppression in the tumor microenvironment and developing effective immune therapies for cancer and autoimmune diseases.
- Location
- In Person
- Cost
- Free